Rami Al Batran
Courriels
rami.al.batran@umontreal.ca (Travail)
Travail 1 : 514 343-6111 #14500
Web : Blogue
Web : Compte Twitter
Web : Google Scholar
Affiliations
Education Programs
- Health Sciences
- Life Sciences
- Health Sciences
Courses
- PHA1140 Fonctionnement normal du corps humain 4
- PHM6076 Lectures dirigées en sciences pharmaceutiques
Expertises
Research projects Expand all Collapse all
Exploring the Hepatoprotective Actions of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Projet de recherche au Canada / 2024 - 2031
Medium Chain Triglycerides and Ketogenesis Projet de recherche au Canada / 2020 - 2027
Investigating the Short- and Long-term Effects of Ketogenic Diet on Atherosclerosis Projet de recherche au Canada / 2023 - 2026
Cibler le métabolisme des corps cétoniques dans l'obésité et le syndrome métabolique Projet de recherche au Canada / 2022 - 2026
Cibler le métabolisme des corps cétoniques dans l'obésité et le syndrome métabolique Projet de recherche au Canada / 2022 - 2026
Medium Chain Triglycerides and Ketogenesis Projet de recherche au Canada / 2020 - 2026
Investigating the Role of Ketone Body Metabolism in Diabetic Kidney Disease Projet de recherche au Canada / 2022 - 2025
Pharmacothérapie du métabolisme du corps cétonique dans l'obésité Projet de recherche au Canada / 2021 - 2025
Could a Ketogenic Diet Slow the Progression of Diabetic Kidney Disease? Projet de recherche au Canada / 2021 - 2024
Réseau de recherche en santé cadiométabolique, diabète et obésité CMDO / Quantitative fluxomics of ketone bodies in diabetic kidney disease (the identified trainee is Abdualrahman Abdualkader and the intercenter collaborator is Dr. Matthieu Ruiz (IRCM)). Projet de recherche au Canada / 2021 - 2024
Branched-Chain Amino Acids and Insulin Resistance Projet de recherche au Canada / 2022 - 2023
Investigating the Role of Ketone Body Metabolism in Diabetic Kidney Disease Projet de recherche au Canada / 2022 - 2023
Pharmacothérapie du métabolisme du corps cétonique dans l'obésité Projet de recherche au Canada / 2020 - 2022
Publications Expand all Collapse all
Selected Publications:
Al Batran R, Gopal K, Capozzi ME, Chahade JJ, Saleme B, Tabatabaei-Dakhili SA, Greenwell AA, Niu J, Almutairi M, Byrne NJ, Masson G, Kim R, Eaton F, Mulvihill EE, Garneau L, Masters AR, Desta Z, Velázquez-Martínez CA, Aguer C, Crawford PA, Sutendra G, Campbell JE, Dyck JRB, and Ussher JR. Pimozide Alleviates Hyperglycemia in Diet-Induced Obesity by Inhibiting Skeletal Muscle Ketone Oxidation. Cell Metabolism. 2020 https://doi.org/10.1016/j.cmet.2020.03.017
Eshreif A, Al Batran R, Jamieson KL, Darwesh AM, Gopal K, Greenwell AA, Zlobine I, Aburasayn H, Eaton F, Mulvihill EE, Campbell JE, Seubert JM, Ussher JR. L-citrulline supplementation improves glucose and exercise tolerance in obese mice. Exp Physiol. 2019 Dec 5. doi: 10.1113/EP088109.
Uddin GM, Zhang L, Shah S, Fukushima A, Wagg CS, Gopal K, Al Batran R, Pherwani S, Ho KL, Boisvenue J, Karwi QG, Altamimi T, Wishart DS, Dyck JRB, Ussher JR, Oudit GY, Lopaschuk GD. Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure. Cardiovasc Diabetol. 2019 Jul 5;18(1):86.
Ho KL, Zhang L, Wagg C, Al Batran R, Gopal K, Levasseur J, Leone T, Dyck JRB, Ussher JR, Muoio DM, Kelly DP, and Lopaschuk GD. Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. Cardiovasc Res. 2019 Feb 18. pii: cvz045.
Al Batran R, Gopal K, Aburasayn H, Eshreif A, Almutairi M, Greenwell AA, Campbell SA, Saleme B, Court EA, Eaton F, Light PE, Sutendra G, Ussher JR. The antianginal ranolazine mitigates obesity-induced hepatic steatosis and increases hepatic dehydrogenase activity. JCI Insight. 2019 Jan 10;4(1). pii: 124643.
Al Batran R, Gopal K, Martin MD, Ho KL, Almutairi M, Aburasayn H, Eaton F, Campbell JE, Ussher JR. Skeletal muscle-specific Cre recombinase expression, controlled by the human α-skeletal actin promoter, improves glucose tolerance in mice fed a high-fat diet. Diabetologia. 2018 Aug;61(8):1849-1855.
Gopal K, Almutairi M, Al Batran R, Eaton F, Gandhi M, Ussher JR. Cardiac-specific deletion of pyruvate dehydrogenase impairs glucose oxidation rates and induces diastolic dysfunction. Front Cardiovasc Med. 2018 Mar 6; 5:17.
Al Batran R, Almutairi M, Ussher JR. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism. Peptides. 2018 Feb;100:94-100.
Aburasayn H, Al Batran R, Gopal K, Almutairi M, Eshreif A, Eaton F, Ussher JR. Female offspring born to obese and insulin-resistant dams are not at increased risk for obesity and metabolic dysfunction during early development. Can J Physiol Pharmacol. 2018 Jan;96(1):97-102.
Al Batran R, & Ussher JR. Revisiting protein acetylation and myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol. 2017 Sep 1;313(3):H617-H619
Gopal K, Saleme B, Al Batran R, Aburasayn H, Eshreif A, Ho KL, Ma WK, Almutairi M, Eaton F, Gandhi M, Park EA, Sutendra G, Ussher JR. FoxO1 regulates myocardial glucose oxidation rates via transcriptional control of pyruvate dehydrogenase kinase 4 expression. Am J Physiol Heart Circ Physiol. 2017 Sep 1;313(3):H479-H490.
Aburasayn H, Al Batran R, Ussher JR. Targeting ceramide metabolism in obesity. Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E423-35.
Browse this profile on: